They concluded that CXCL5 may serve as a promoter of colorectal cancer metastasis and a predictor of poor clinical outcomes in colorectal cancer patients and inhibition of the CXCL5/CXCR2 signaling pathway may be a promising target for CRC therapy. The gene discussed is CXCR2; the disease is colorectal carcinoma.